1. Sakai T, Hamada S, Koike H, et al. Is mutation analysis of β-catenin useful for the diagnosis of desmoid-type fibromatosis? A systematic review. Jpn J Clin Oncol 2020;50:1037-42.
2. Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica 2021;113:70-84.
3. Timbergen MJM, Schut AW, Grünhagen DJ, et al. Active surveillance in desmoid-type fibromatosis: A systematic literature review. Eur J Cancer 2020;137:18-29.
4. Cuomo P, Scoccianti G, Schiavo A, et al. Extra-abdominal desmoid tumor fibromatosis: a multicenter EMSOS study. BMC Cancer 2021;21:437.
5. Lorenzen J, Cramer M, Buck N, et al. Desmoid Type Fibromatosis of the Breast: Ten-Year Institutional Results of Imaging, Histopathology, and Surgery. Breast Care (Basel) 2021;16:77-84.
6. Wuyts L, De Schepper A. Desmoid-type Fibromatosis of the Breast Mimicking Carcinoma. J Belg Soc Radiol 2019;103:13.
7. Raguzzi E, Duhoux F, Mazzeo F, et al. Breast desmoid tumor with spectacular evolution: a case report and review of current treatment options. Clinics of Surgery 2019;1:15.
8. Duazo-Cassin L, Le Guellec S, Lusque A, et al. Breast desmoid tumor management in France: toward a new strategy. Breast Cancer Res Treat 2019;176:329-35.
9. Norkowski E, Masliah-Planchon J, Le Guellec S, et al. Lower Rate of CTNNB1 Mutations and Higher Rate of APC Mutations in Desmoid Fibromatosis of the Breast: A Series of 134 Tumors. Am J Surg Pathol 2020;44:1266-73.
10. Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer 2020;127:96-107.
11. Costa PA, Marbin S, Costa BMLA, et al. A nonrandom association of breast implants and the formation of desmoid tumors. Breast J 2021;27:768-75.
12. Rakha EA, Brogi E, Castellano I, et al. Spindle cell lesions of the breast: a diagnostic approach. Virchows Arch 2022;480:127-45.
13. Wongmaneerung P, Somwangprasert A, Watcharachan K, et al. Bilateral desmoid tumor of the breast: case seriesand literature review. Int Med Case Rep J 2016;9:247-51.
14. Taylor TV, Sosa J. Bilateral breast fibromatosis: case report and review of the literature. J Surg Educ 2011;68:320-5.
15. Brown CS, Jeffrey B, Korentager R, et al. Desmoid tumors of the bilateral breasts in a patient without Gardner syndrome: a case report and review of literature. Ann Plast Surg 2012;69:220-2.
16. Al-Khyatt W, Goyal A, Mansel RE. Nipple-sparing skinsparing mastectomy and vertical latissimus dorsi flap reconstruction for bilateral fibromatosis of the breast. Clin Breast Cancer 2010;10:E1-2.
17. Silva S, Lage P, Cabral F, et al. Bilateral breast fibromatosis after silicone prosthetics in a patient with classic familial adenomatous polyposis: A case report. Oncol Lett 2018;16:1449-54.
18. Papantoniou V, Koutsikos J, Sotiropoulou M, et al. Recurrent bilateral mammary fibromatosis (desmoid tumor) imaged with technetium-99m pentavalent dimercaptosuccinic acid [99mTc-(V)DMSA] scintimammography. Gynecol Oncol 2005;97:964-9.
19. Liao GJ, Henze Bancroft LC, Strigel RM, et al. Background parenchymal enhancement on breast MRI: A comprehensive review. J Magn Reson Imaging 2020;51:43-61.
20. Li GZ, Raut CP, Hunt KK, et al. Breast Sarcomas, Phyllodes Tumors, and Desmoid Tumors: Epidemiology, Diagnosis, Staging, and Histology-Specific Management Considerations. Am Soc Clin Oncol Educ Book 2021;41:390-404.
21. Magro G. Differential Diagnosis of Benign Spindle Cell Lesions. Surg Pathol Clin 2018;11:91-121.
22. Magro G, Salvatorelli L, Puzzo L, et al. Practical approach to diagnosis of bland-looking spindle cell lesions of the breast. Pathologica 2019;111:344-60.
23. Liu H, Zeng H, Zhang H, et al. Breast fibromatosis: Imaging and clinical findings. Breast J 2020;26:2217-22.
24. D'Orsi CJ. 2013 ACR BI-RADS Atlas: Breast Imaging Reporting and Data System. 5th Edition. American College of Radiology, 2014.
25. Li M, Cordon-Cardo C, Gerald WL, et al. Desmoid fibromatosis is a clonal process. Hum Pathol 1996;27:939-43.
26. Koike H, Hamada S, Sakai T, et al. Is tumour location a prognostic factor for pharmacological treatment in patients with desmoid-type fibromatosis? a systematic review. Jpn J Clin Oncol 2020;50:1032-6.
27. Ng TL, Gown AM, Barry TS, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 2005;18:68-74.
28. van Houdt WJ, Wei IH, Kuk D, et al. Yield of Colonoscopy in Identification of Newly Diagnosed Desmoid-Type Fibromatosis with Underlying Familial Adenomatous Polyposis. Ann Surg Oncol 2019;26:765-71.
29. Nathenson MJ, Hu J, Ratan R, et al. Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study. Clin Cancer Res 2022;28:4092-104.
30. Kito M, Ogose A, Yoshida M, et al. Usefulness of surgical treatment for asymptomatic patients with extra-peritoneal desmoid-type fibromatosis: a systematic review and metaanalysis. Jpn J Clin Oncol 2020;50:574-80.
31. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
32. Gounder MM, Mahoney MR, Van Tine BA, et al. Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med 2018;379:2417-28.
33. Kasper B, Gruenwald V, Reichardt P, et al. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer 2017;76:60-7.
34. Toulmonde M, Pulido M, Ray-Coquard I, et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol 2019;20:1263-72.
35. Penel N, Coindre JM, Bonvalot S, et al. Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. Eur J Cancer 2016;58:90-6.
36. Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;32:1348-65.
